BioCentury
ARTICLE | Company News

Amgen, ImmunoGen, Oxford BioTherapeutics deal

May 12, 2014 7:00 AM UTC

Oxford received exclusive, worldwide rights to Xenomouse antibodies generated by Amgen and to ImmunoGen's TAP antibody-conjugate technology for an undisclosed target. Oxford will use the antibodies an...